NASDAQ:BYSI

BeyondSpring Q3 2026 Earnings Results & Report

BeyondSpring logo
$0.56 -0.02 (-3.27%)
Closing price 04:00 PM Eastern
Extended Trading
$0.56 0.00 (-0.70%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeyondSpring beat analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.05 versus the -$0.54 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
4:00 PM ET

BeyondSpring EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.54
Beat/Miss
Beat by +$0.49
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

BeyondSpring Revenue Results

Actual Revenue
N/A
Expected Revenue
$8.77 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

BeyondSpring's Q4 2026 earnings is estimated for Thursday, December 17, 2026, based on past reporting schedules

BeyondSpring Q3 2026 Earnings FAQ

BeyondSpring (NASDAQ:BYSI) reported earnings of -$0.05 per share for Q3 2026, beating the consensus estimate of -$0.54. The report was announced on Friday, November 13, 2026.

BeyondSpring's next earnings date is estimated for Thursday, December 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for BeyondSpring on the company's earnings history page.

BeyondSpring Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
BeyondSpring (BYSI) Set to Post Earnings on Thursday
See More BeyondSpring Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeyondSpring? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeyondSpring and other key companies, straight to your email.

About BeyondSpring

BeyondSpring (NASDAQ:BYSI) is a biopharmaceutical company focused on developing therapies for cancer and complications associated with cancer treatment. Its research and development activities center on oncology drug candidates and supportive-care treatments.

The company’s lead candidate is plinabulin, a small-molecule drug being investigated for use in preventing chemotherapy-induced neutropenia, a potentially serious drop in infection-fighting white blood cells. BeyondSpring has also studied plinabulin for its potential anti-cancer effects, including in lung cancer.

Founded in 2010, BeyondSpring has pursued clinical development in the United States and Asia. Co-founder Lan Huang has served as the company’s chief executive officer and chairman.

View BeyondSpring Profile